I have to admit that I put on my California 'blinders' every now and then. This is one case where I got surprised to see what is going on in the global setting of drug traceability. I read this superb IndustryWeek article that frames, yet again, the pain induced when there is a general lack of harmonization, Global Drug Traceability Mandates: Why Act Now? - Should pharmaceutical companies sit back and wait for someone else to blaze the drug traceability trail? Author Brian Daleiden taps into my Californa (CA) blindspot by stating, "California decided to go one step further and include an item-level drug serialization requirement in their state mandates. Given the significant incremental investment this would require, it was no surprise when the start date for CA compliance was pushed back to 2015, giving the industry a sigh of relief. But should it? A closer look at the current domestic landscape should give pause to anyone feeling too comfortable." In a nutshell, the article's conclusion challenges us to think about whether companies are making the right decisions, "The myriad of business and regulatory issues confronting most companies along the global pharmaceutical supply chain can be daunting. Against such uncertainty, it is understandable that the temptation is to take the path of least resistance and isolate and tackle each issue as it comes. Unfortunately, it is becoming clearly apparent that the industry has reached a tipping point where this approach will no longer work. The operational costs and business risks are just too high." Global Drug Traceability Mandates: Why Act Now? - Should pharmaceutical companies sit back and wait for someone else to blaze the drug traceability trail? (displayed on one page)
Posts
Europe Strengthens Future Disease Defense
1 hour ago
No comments:
Post a Comment